Nanox Imaging Ltd. (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a distribution agreement with Technologic s.r.l., an Italian company affiliated with Tecnologie Avanzate, to commercialize its AI-powered bone health solution, HealthOST, in Italy. The agreement is intended to expand Nanox AI’s commercial presence in the Italian market, leveraging Technologic’s experience and local market knowledge. HealthOST analyzes eligible routine CT scans to provide qualitative and quantitative assessments of the spine, helping clinicians identify patients who may benefit from further evaluation for musculoskeletal conditions such as osteoporosis.
This development matters because it represents a significant step in Nanox’s strategy to drive the global transition to preventive health care through its integrated imaging and AI platform. By partnering with a local distributor, Nanox can accelerate the adoption of HealthOST in a key European market, potentially leading to earlier detection of osteoporosis—a condition that often goes undiagnosed until a fracture occurs. The agreement also underscores the growing role of AI in radiology, where algorithms can extract additional clinical value from routine scans without requiring extra procedures or radiation exposure.
Nanox, through its various subsidiaries, focuses on delivering an end-to-end medical imaging and healthcare services platform that combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace. The company’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
For investors, the Italian distribution agreement signals progress in Nanox’s commercialization efforts for its AI products, which could drive revenue growth and strengthen its position in the global medical imaging market. The latest news and updates relating to NNOX are available in the company’s newsroom at http://ibn.fm/NNOX. To view the full press release, visit https://ibn.fm/y9Zro.
As a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BioMedWire is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer. BioMedWire is powered by IBN.
